Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$13M
1 round on record
Latest round
$13M
Venture round · Jul 2024 · 2 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 9, 2024 Raised a round Venture round $13M · SEC Form D 2023 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jul 2024 $13M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Valora Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Miguel Garcia-GuzmanExecutive Officer, DirectorSEC Form D
Similar startupsby what they do, their industry and backers
Oblenio BioSeries B $62M · 4 mo ago · 51-200 employees
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell…
Boomerang MedicalSeries B $20M · 13 mo ago · 51-200 employees
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
Ditto Bio11-50 employees
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Coultreon BiopharmaSeries A $125M · 5 mo ago · 51-200 employees
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Octagon TherapeuticsVenture round $11M · 2 yr ago · Founded 2016 · 11-50 employees
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
Quercis Pharma develops Kinisoquin™, a first-in-class oral PDI inhibitor in Phase 3 for the prevention of cancer-associated thrombosis…

Overview

Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.

People

Miguel Garcia-Guzman
Executive Officer, Director
Sanford Madigan
Director
Stefan Heller
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
La Jolla United States
HQ
10-50 est. staff

Financials

Total raised
$13M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $13M Details